1,948 reports of this reaction
3.4% of all LAMIVUDINE reports
#2 most reported adverse reaction
VIROLOGIC FAILURE is the #2 most commonly reported adverse reaction for LAMIVUDINE, manufactured by ViiV Healthcare Company. There are 1,948 FDA adverse event reports linking LAMIVUDINE to VIROLOGIC FAILURE. This represents approximately 3.4% of all 57,073 adverse event reports for this drug.
Patients taking LAMIVUDINE who experience virologic failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIROLOGIC FAILURE is moderately reported among LAMIVUDINE users, representing a notable but not dominant share of adverse events.
In addition to virologic failure, the following adverse reactions have been reported for LAMIVUDINE:
The following drugs have also been linked to virologic failure in FDA adverse event reports:
VIROLOGIC FAILURE has been reported as an adverse event in 1,948 FDA reports for LAMIVUDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIROLOGIC FAILURE accounts for approximately 3.4% of all adverse event reports for LAMIVUDINE, making it one of the most commonly reported side effect.
If you experience virologic failure while taking LAMIVUDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.